Rigel Announces Initiation Of Phase II Study Evaluating R788 In Rheumatoid Arthritis
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced today that it has initiated enrollment and dosing in a Phase II study evaluating the efficacy andsafety of its lead product candidate, R788, an oral syk kinase inhibitor,for the treatment of patients with rheumatoid arthritis (RA). “As an oral agent with the potential to modify the course of RA, R788is a very attractive product candidate for the treatment of this disease,”said Elliott B. Grossbard, M.D. [click link for full article]
Lower Back Pain
Title: Lower Back Pain
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 9/21/2006
Vioxx Successor Arcoxia May Have Similar Heart Attack Risks
Arcoxia, a new experimental painkiller Merck & Co hope will become the successor of Vioxx, which was taken off the market because of its heart attack risks, may have similar risks, say scientists who looked at 23 clinical trials comparing several painkillers.You can read about this new report in JAMA (the Journal of the American Medical Association). [click link for full article]
